Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

30 citing papers in PubMed, 83 citations in OpenAlex.

1. Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).Diabetes care · 2025 · on this map
   Trial
2. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.Diabetologia · 2014
   Trial
3. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.Diabetologia · 2014 · on this map
   Trial
4. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.International journal of clinical practice · 2013
   Trial
5. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.British journal of clinical pharmacology · 2010
   Trial
6. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).Diabetic medicine : a journal of the British Diabetic Association · 2009 · on this map
   Trial
7. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.Diabetes care · 2009 · on this map
   Trial
8. Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression.Medicina (Kaunas, Lithuania) · 2026
   Review
9. Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans.The Journal of clinical endocrinology and metabolism · 2025
   Article
10. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.Obesity facts · 2023
    Review
11. The Role of Anti-Obesity Medication in Prevention of Diabetes and Its Complications.Journal of obesity & metabolic syndrome · 2019
    Review
12. Liraglutide modulates adipokine expression during adipogenesis, ameliorating obesity, and polycystic ovary syndrome in mice.Endocrine · 2019
    Article
13. Controlled release of liraglutide using thermogelling polymers in treatment of diabetes.Scientific reports · 2016
    Article
14. Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?Pharmacological research · 2015
    Review
15. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes.Journal of clinical biochemistry and nutrition · 2013
    Article
16. The once-daily human glucagon-like peptide-1 analog, liraglutide, improves β-cell function in Japanese patients with type 2 diabetes.Journal of diabetes investigation · 2012 · on this map
    Article
17. Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2012
    Article
18. Regulation of adipocyte formation by GLP-1/GLP-1R signaling.The Journal of biological chemistry · 2012
    Article
19. Liraglutide: a review of its use in the management of type 2 diabetes mellitus.Drugs · 2011
    Review
20. The efficacy and safety of liraglutide.International journal of clinical pharmacy · 2011
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors at 3 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as